Drug intelligence / Profile preview

interleukin-2 + rapamycin

Development stage: Unknown
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
Administration: Subcutaneous, Oral

Overview

A combination therapy consisting of interleukin-2 (IL-2) and rapamycin (sirolimus). This combination works by modulating the immune system, particularly through effects on regulatory T cells (Tregs). Rapamycin inhibits the mammalian target of rapamycin (mTOR), suppressing T-cell activation and proliferation, while low-dose IL-2 selectively expands regulatory T cells. Together, they appear to create a balanced immune response that may be beneficial in autoimmune conditions and transplantation settings.

Brand names: RapamuneProleukin
Other names: IL-2 + rapamycinIL-2 + sirolimuslow-dose IL-2 + rapamycinLd-IL2 + rapamycin

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on interleukin-2 + rapamycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on interleukin-2 + rapamycin.

Explore the full profile